Intravenous Amrinone: An Advance or a Wrong Step?
Authors: JOSEPH A. FRANCIOSA
Journal: Annals of Internal Medicine (1985)

Editorials1 March 1985Intravenous Amrinone: An Advance or a Wrong Step?JOSEPH A. FRANCIOSA, M.D.JOSEPH A. FRANCIOSA, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-3-399 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAmrinone is a nonglycosidic, non-catecholamine-dependent, inotropic vasodilator agent that has recently been made available for intravenous use in patients with severe heart failure. Because other agents, such as dopamine, dobutamine, and nitroprusside, are available and have actions similar to those of amrinone in patients with heart failure, the usefulness of this newer agent must be put in perspective.Amrinone is advertised as a "major advance" in inotropic therapy because of its alleged advantages of more sustained action than dopamine or dobutamine and reduction of myocardial oxygen demand. The evidence for these claims and their importance appears minimal. Recent reports indicate...References1. WILMSHURSTTHOMPSONJENKINSCOLTARTWEBB-PEPLOE PDBDM. Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J. 1983;49:77-82. CrossrefMedlineGoogle Scholar2. WILMSHURSTWALKERFRY PJC. Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovasc Res. 1984;18:302-9. CrossrefMedlineGoogle Scholar3. HERMILLERLEITHEMAGORIENUNVERFERTHLEIER JMRDC. Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. J Pharmacol Exp Ther. 1984;228:319-26. MedlineGoogle Scholar4. WILMSHURSTTHOMPSONJUULJENKINSCOLTARTWEBB-PEPLOE PDSBDM. Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br Heart J. 1984;52:38-48. CrossrefMedlineGoogle Scholar5. KLEINSISKINDFRISHMANSONNENBLICKLEJEMTEL NSWET. Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. Am J Cardiol. 1981;48:170-5. CrossrefMedlineGoogle Scholar6. EDELSONLEJEMTELALOUSIBIDDLECOMEMASKINSONNENBLICK JTACCE. Relationship between amrinone plasma concentration and cardiac index. Clin Pharmacol Ther. 1981;29:723-8. CrossrefMedlineGoogle Scholar7. BENOTTIGROSSMANBRAUNWALDCARABELLO JWEB. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation. 1980;62:28-34. CrossrefMedlineGoogle Scholar8. DUNKMANWILENFRANCIOSA WMJ. Adverse effects of long-term amrinone administration in congestive heart failure. Am Heart J. 1983;105:861-3. CrossrefMedlineGoogle Scholar9. WILMSHURSTWEBB-PEPLOE PM. Side effects of amrinone therapy. Br Heart J. 1983;49:447-51. CrossrefMedlineGoogle Scholar10. LEIERDALPIAZHUSS CKP. Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;52:304-8. CrossrefMedlineGoogle Scholar11. KINNEYCARLINBALLARDBURKSHALLAHANZELIS EBJJWR. Clinical experience with amrinone in patients with advanced congestive heart failure. J Clin Pharmacol. 1982;22:433-40. CrossrefMedlineGoogle Scholar12. NACCARELLIGRAYDOUGHERTYHANNAGOLDSTEIN GEAJR. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol. 1984;54:600-4. CrossrefMedlineGoogle Scholar13. SIEGELLEJEMTELSTROM LTJ. Improvement in exercise capacity despite cardiac deterioration: noninvasive assessment of long-term therapy with amrinone in severe heart failure. Am Heart J. 1983;106:1042-7. CrossrefMedlineGoogle Scholar14. LIKOFFWEBERANDREWS MKV. Amrinone in the treatment of chronic cardiac failure. J Am Coll Cardiol. 1984;3:1282-90. CrossrefMedlineGoogle Scholar15. FRANCIOSA J. Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure. Prog Cardiovasc Dis. 1982;14:319-30. CrossrefGoogle Scholar16. KATZ A. A new inotropic drug: its promise and a caution [Editorial]. N Engl J Med. 1978;299:1409-10. CrossrefMedlineGoogle Scholar17. DIBIANCOSHABETAISILVERMANLEIERBENOTTI RRBCJ. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol. 1984;4:855-66. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Arkansas for Medical Sciences Little Rock, Arkansas PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIntravenous Vasodilator Therapy in Congestive Heart FailureCongestive heart failure and pulmonary edema for the emergency physicianPhosphodiesterase Inhibitors in Heart Failure: An OverviewPharmacology, Monitoring, and Nutritional SupportThe effects of amrinone versus dobutamine on myocardial mechanics and energetics after hypothermic global ischemiaCardiac performance and systemic oxygen transport after cardiopulmonary bypass surgeryEffect of medications on cardiac outputIntensive Care TherapeuticsCongestive Heart FailureLow-dose enoximone in subjects awaiting cardiac transplantationMedical Therapy Tailored for Advanced Heart FailureHaemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogsDobutamine potentiates amrinone's beneficial effects in moderate but not in advanced heart failure. 31P-MRS in isolated hamster hearts.Amrinone: Is it the inotrope of choice?The Use of Inotropic Agents in Acute and Chronic Congestive Heart FailureEffect of amrinone on myocardial mitochondria functionWhat's New in Cardiac Drugs?Vasodilators: Rationale and Practical UseCombined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprussideComparative study of cardiovascular profiles of milrinone and amrinone by use of isolated, blood-perfused dog heart preparationsNew Positive Inotropic Agents for Congestive Heart FailureThe likely impact on drug regulation in AustraliaNew Positive Inotropic Agents in the Treatment of Congestive Heart FailureChronic congestive heart failure: Where have we been? Where are we heading?Intravenous AmrinoneRICHARD A. GOLDSTEIN, M.D., GERALD V. NACCARELLI, M.D. 1 March 1985Volume 102, Issue 3Page: 399-400KeywordsDopamineHeart failureOxygenVasodilators Issue Published: 1 March 1985 PDF downloadLoading ...